<description>&lt;p&gt;Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-responding patients with advanced NSCLC, weighing efficacy, potential toxicity, and cost concerns.&lt;/p&gt;</description>

The Beacon

H. Jack West, MD

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

MAR 8, 201920 MIN
The Beacon

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

MAR 8, 201920 MIN

Description

Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-responding patients with advanced NSCLC, weighing efficacy, potential toxicity, and cost concerns.